Anti-PAR4 Antibody detects endogenous levels of total PAR4 protein.
F2R-like thrombin or trypsin receptor 3/coagulation factor 2 receptor-like 3 (F2RL3) gene codes for protease-activated receptor 4 (PAR4) protein. PAR4 belongs to the G protein-coupled receptors (GPCRs) family. It is expressed at high levels in the lungs, pancreas, thyroid, testis, and small intestine. PAR4 gene is located on human chromosome 19p12. Anti-PAR4 antibody detects endogenous levels of total PAR4 protein.
免疫原
The antiserum was produced against synthesized peptide derived from human PAR4.
Immunogen Range: 29-78
アプリケーション
Anti-PAR4 antibody produced in rabbit has been used in immunoblotting (1:1000).[1]
生物化学的/生理学的作用
Protease-activated receptor 4 (PAR4) protein is involved in vascular inflammation. It is necessary for a stable thrombus as it mediates persistent thrombin signaling in platelets. PAR4 aids pro-inflammatory actions by interacting with the bradykinin B2 receptor. It is linked to renal function and the development of chronic kidney disease (CKD).
特徴および利点
Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.
物理的形状
ウサギIgGのPBS溶液(Mg2+およびCa2+を含まず)、pH 7.4、150 mM NaCl、0.02% アジ化ナトリウム、50% グリセロール
免責事項
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
International journal of molecular sciences, 19(2) (2018-02-15)
Cardiovascular diseases (CVDs) are currently among the leading causes of death worldwide. Platelet aggregation is a key cellular component of arterial thrombi and major cause of CVDs. Protease-activated receptors (PARs), including PAR1, PAR2, PAR3 and PAR4, fall within a subfamily
Inflammatory diseases have become increasingly prevalent with industrialization. To address this, numerous anti-inflammatory agents and molecular targets have been considered in clinical trials. Among molecular targets, protease-activated receptors (PARs) are abundantly recognized for their roles in the development of chronic
Protease-activated receptor 4 (PAR4) mediates sustained thrombin signaling in platelets and is required for a stable thrombus. PAR4 is activated by proteolysis of the N terminus to expose a tethered ligand. The structural basis for PAR4 activation and the location
The F2RL3 gene encoding protease activated receptor 4 (PAR4) contains a single nucleotide variant, rs773902, that is functional. The resulting PAR4 variants, Thr120, and Ala120, are known to differently affect platelet reactivity to thrombin. Significant population differences in the frequency
Proceedings of the National Academy of Sciences of the United States of America, 95(12), 6642-6646 (1998-06-17)
Protease-activated receptors 1-3 (PAR1, PAR2, and PAR3) are members of a unique G protein-coupled receptor family. They are characterized by a tethered peptide ligand at the extracellular amino terminus that is generated by minor proteolysis. A partial cDNA sequence of